Categories
Lung Cancer

Australian scientists trial cancer vaccine that could revolutionise lung cancer treatment [Video]

It is one of the most commonly-diagnosed cancers in the country, and lung cancer claims a life almost every hour, around the …

Watch/Read More
Categories
Lung Cancer

SPOTLIGHT: zolbetuximab and m-FOLFOX6 in CLDN18.2+, HER2- GEJ cancer [Video]

Kohei Shitara, MD, National Cancer Center Hospital East, Chiba, Japan, provides an overview of findings from the Phase III SPOTLIGHT trial (NCT03504397), which assessed zolbetuximab in patients with CLDN18.2-positive, HER2-negative, locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Zolbetuximab is a first-in-class monoclonal antibody targeting CLDN18.2, and patients were given modified-FOLFOX6 with or without zolbetuximab. 2735 patients were recruited, and addition of zolbetuximab significantly improved progression-free survival and overall survival. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.